Portal de Periódicos da CAPES

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small-cell lung cancer and no other actionable oncogenic driver

2021; Impact Journals LLC; Volume: 12; Issue: 18 Linguagem: Inglês

10.18632/oncotarget.28045

1949-2553

Marta Domènech, Ana M Muñoz‐Mármol, José Luís Mate, Anna Estival, Teresa Morán, Marc Cucurull, Maria Saigí, Ainhoa Hernández, Carolina Sanz, Alba Hernández-Gallego, Aintzane Urbizu, Anna Martínez‐Cardús, Adrià Bernat-Peguera, Enric Carcereny,

Cancer Cells and Metastasis

// Marta Domènech 1 , 3 , Ana M. Muñoz Marmol 2 , Jose Luis Mate 2 , Anna Estival 1 , 3 , Teresa Moran 1 , 3 , Marc Cucurull 1 , 3 , Maria Saigi 1 , 3 , Ainhoa Hernandez 1 , 3 , Carolina Sanz 2 , Alba Hernandez-Gallego 2 , Aintzane Urbizu 2 , Anna Martinez-Cardus 3 , Adrià Bernat 3 and Enric Carcereny 1 , 3 1 Medical Oncology Department, Catalan Institute of Oncology Badalona, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain 2 Pathology Department, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain 3 Badalona Applied Research Group in Oncology (BARGO), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain Correspondence to: Enric Carcereny, email: ecarcereny@iconcologia.net Keywords: non-small cell lung cancer; oncogenic driver; PD-L1; MET amplification; smoking habit Received: May 31, 2021     Accepted: July 28, 2021     Published: August 31, 2021 Copyright: © 2021 Domènech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Non-small cell lung cancers (NSCLC) are the most common type of lung cancer and can be classified according to the presence of mutually exclusive oncogenic drivers. The majority of NSCLC patients present a non-actionable oncogenic driver, and treatment resistance through the amplification of the MET proto-oncogene ( MET ) or the expression of programmed cell death protein 1 ligand (PD-L1) is common. Herein, we investigated the relation between MET gene amplification and PD-L1 expression in patients with advanced NSCLC and no other actionable oncogenic driver (i.e., EGFR , ALK , ROS1 ). Our retrospective observational study analyzed data from 48 patients (78% men, median age 66 years) admitted to the Germans Trias i Pujol Hospital, Spain, between July 2015 and February 2019. Patients presenting MET amplification showed a higher proportion of PD-L1 expression (93% vs. 39%; p < 0.001) and overexpression (64% vs. 27%; p = 0.020) than those with non-amplified MET . PD-L1 expression was not significantly different when analyzed by sex ( p = 0.624), smoking history ( p = 0.429), and Eastern Cooperative Oncology Group Performance Status ( p = 0.597) Overall survival rates were not significantly affected by MET amplification (high and intermediate amplification vs low amplification and non-amplificated) ( p = 0.252) nor PD-L1 expression (> vs =< 50%) ( p = 0.893). In conclusion, a positive correlation was found between MET gene amplification and PD-L1 expression and highly expressed (above 50%) in patients with NSCLC and no other actionable oncogenic driver. It could be translated as new guided-treatment oportunities for these patients.